Long‐term use of dienogest for the treatment of primary and secondary dysmenorrhea

Journal of Obstetrics and Gynaecology Research - Tập 46 Số 4 - Trang 606-617 - 2020
Yutaka Osuga1, Kôichi Hayashi2, Shingo Kanda2
1Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan
2Clinical Development Department, Mochida Pharmaceutical Co., Ltd., Tokyo, Japan

Tóm tắt

AbstractAimTo investigate the safety and efficacy of dienogest (DNG), a progestational 19‐norsteroid, administered for 52 weeks in patients with primary and secondary dysmenorrhea.MethodsA total of 147 patients with dysmenorrhea received 1 mg of DNG orally each day for 52 weeks. The dose could be increased to 2 mg/day at or after Week 12 according to the investigator's determination. The primary safety endpoint was evaluation of adverse events, and the secondary safety endpoint was evaluation of adverse drug reactions. The number of days and severity of genital bleeding were assessed according to records in the patients' diary. Lower abdominal pain and/or low back pain because of dysmenorrhea were assessed according to the dysmenorrhea score.ResultsThe most frequent adverse drug reaction was irregular uterine bleeding (94.6%). Most subjects completed the 52‐week administration. Genital bleeding was more likely to occur in subjects with secondary dysmenorrhea than in those with primary dysmenorrhea, and in subjects with “uterine myoma or adenomyosis” than in those with “endometriosis alone.” In any of the categorizations, there tended to be fewer days with genital bleeding as the treatment period increased in length, and most of the genital bleeding cases were mild. The change from baseline in the dysmenorrhea score (mean ± standard deviation [SD]) was −3.7 ± 1.6 at Week 24 of treatment and −4.0 ± 1.3 at Week 52.ConclusionThis study showed favorable tolerability of the long‐term use of DNG to patients with dysmenorrhea and a sustainable pain relief effect.

Từ khóa


Tài liệu tham khảo

10.1093/humupd/dmv039

Osayande AS, 2014, Diagnosis and initial management of dysmenorrhea, Am Fam Physician, 89, 341

10.3111/13696998.2013.830974

10.1136/bmj.332.7550.1134

Marjoribanks J, 2015, Nonsteroidal anti‐inflammatory drugs for dysmenorrhoea, Cochrane Database Syst Rev, 7, CD001751

Momoeda M, 2014, Does the presence of coexisting diseases modulate the effectiveness of a low‐dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women, Int J Womens Health, 6, 989

10.1016/j.fertnstert.2016.08.051

10.1016/j.ejogrb.2005.10.029

10.1016/j.contraception.2006.12.008

10.1016/j.steroids.2007.10.003

10.2165/00044011-199918040-00003

10.1016/j.fertnstert.2017.07.021

10.1016/j.fertnstert.2007.03.042

10.1111/j.1447-0756.2009.01076.x

10.1111/jog.13406

10.1111/j.1447-0578.2007.00189.x

10.1016/j.fertnstert.2019.09.014

10.1016/j.fertnstert.2007.08.051

10.1016/S0895-4356(98)00095-X

Fukuhara S, 2001, Manual of SF‐36 Japanese version 1.2

Barbieri RL, 1998, Endometriosis and the estrogen threshold theory. Relation to surgical and medical treatment, J Reprod Med, 43, 287

10.1177/0091270011423664

10.1136/bmj.b2890

10.1136/bmj.b2921

10.1136/bmj.d6423

10.1136/bmj.e4944

10.1016/j.thromres.2015.09.011

10.1016/j.fertnstert.2019.09.014

10.1016/j.ajog.2009.10.857

10.1093/humupd/dmq042

Thông tin
Thông tin xuất bản

Journal of Obstetrics and Gynaecology Research

Tập 46 Số 4

606-617

Thông tin tác giả